Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01406574 | Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 23 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00493883 | Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors | completed | Phase 1 / Phase 2 | 81 | Southwestern Regional Medical CenterOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00107536 | Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00006016 | Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01003015 | Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 36 | BayerINDUSTRY | 4 | Apr 3, 2015 | clinicaltrials |
| NCT00056992 | Testing of ADI-PEG in Hepatocellular Carcinoma | completed | Phase 2 | 34 | FDA Office of Orphan Products DevelopmentFED | 1 | Mar 25, 2015 | clinicaltrials |
| NCT00108953 | A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 96 | BayerINDUSTRY | 6 | Oct 31, 2014 | clinicaltrials |
| NCT00083226 | Doxorubicin and Bortezomib in Treating Patients With Liver Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00627042 | Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy | completed | Phase 2 | 42 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 8, 2014 | clinicaltrials |
| NCT02202564 | Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 81 | Huazhong University of Science and TechnologyOTHER | 0 | Jul 29, 2014 | clinicaltrials |
| NCT00484211 | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 40 | AGC Biologics S.p.A.INDUSTRY | 1 | May 30, 2014 | clinicaltrials |
| NCT00604721 | Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00639509 | IMC-A12 in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00044512 | A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma | completed | Phase 2 | 137 | BayerINDUSTRY | 5 | Apr 16, 2014 | clinicaltrials |
| NCT00142428 | Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT00142467 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT00361309 | SU011248 in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT01116635 | Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 24 | University of British ColumbiaOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00943449 | 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma(Shelter) | completed | Phase 2 | 57 | 4SC AGINDUSTRY | 2 | Jan 16, 2014 | clinicaltrials |
| NCT01204177 | Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.(BASIL) | completed | Phase 2 | 70 | BayerINDUSTRY | 4 | Sep 6, 2013 | clinicaltrials |
| NCT01934829 | Urea Cream Treatment Sorafenib-Associated HSFR in HCC | completed | Phase 2 | 871 | Chinese Anti-Cancer AssociationOTHER | 1 | Sep 4, 2013 | clinicaltrials |
| NCT00052364 | Oxaliplatin in Treating Patients With Liver Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00238394 | Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00033462 | Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00077441 | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00242502 | Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2013 | clinicaltrials |
| NCT00988741 | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | completed | Phase 2 | 107 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 5 | Feb 28, 2013 | clinicaltrials |
| NCT00071994 | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT01394497 | Use of N-Acetylcysteine During Liver Procurement | completed | Phase 2 | 140 | Azienda Ospedaliera di PadovaOTHER | 1 | Feb 18, 2013 | clinicaltrials |
| NCT00517920 | Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 44 | AbbVie (prior sponsor, Abbott)INDUSTRY | 4 | Jan 4, 2013 | clinicaltrials |
| NCT00614913 | Proton Beam Therapy for Treatment of Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 76 | Loma Linda UniversityOTHER | 1 | Aug 20, 2012 | clinicaltrials |
| NCT00080236 | Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation | completed | Phase 2 | 99 | Conatus Pharmaceuticals Inc.INDUSTRY | 2 | Aug 10, 2012 | clinicaltrials |
| NCT00731445 | Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 43 | Zeria PharmaceuticalINDUSTRY | 1 | Jul 3, 2012 | clinicaltrials |
| NCT01008358 | Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 20 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Jun 8, 2012 | clinicaltrials |
| NCT00919009 | Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 50 | National Cancer Center, KoreaOTHER_GOV | 1 | May 30, 2012 | clinicaltrials |
| NCT00867750 | SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma(SIRTACE) | completed | Phase 2 | 28 | Sirtex MedicalINDUSTRY | 2 | May 7, 2012 | clinicaltrials |
| NCT00775073 | Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001 | completed | Phase 2 | 33 | Gerhard TreiberINDIV | 1 | Apr 30, 2012 | clinicaltrials |
| NCT00784290 | Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 35 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 26, 2012 | clinicaltrials |
| NCT01092091 | Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)(BCT-100-002) | completed | Phase 1 / Phase 2 | 20 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Mar 14, 2012 | clinicaltrials |
| NCT00519688 | UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 44 | National Taiwan University HospitalOTHER | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00703365 | Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 45 | Mahidol UniversityOTHER | 1 | Aug 29, 2011 | clinicaltrials |
| NCT00073736 | Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 28 | Ligand PharmaceuticalsINDUSTRY | 3 | Aug 12, 2011 | clinicaltrials |
| NCT00287222 | Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 21 | University of ArkansasOTHER | 1 | Jul 15, 2011 | clinicaltrials |
| NCT00882869 | XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 75 | Aegera TherapeuticsINDUSTRY | 1 | Jul 13, 2011 | clinicaltrials |
| NCT00910572 | Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma | completed | Phase 2 | 60 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jul 1, 2011 | clinicaltrials |
| NCT00559455 | Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 38 | SanofiINDUSTRY | 1 | Jun 28, 2011 | clinicaltrials |
| NCT00933816 | Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy(SILIUS) | completed | Phase 1 / Phase 2 | 37 | Kindai UniversityOTHER | 1 | Nov 25, 2010 | clinicaltrials |
| NCT00768937 | Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 22 | Medical University of ViennaOTHER | 1 | Nov 9, 2010 | clinicaltrials |
| NCT00490685 | Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 142 | Istituto Clinico HumanitasOTHER | 1 | Sep 2, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2015source: clinicaltrials